Brief: Quest Pharmatech says unit signs agreement with Shenzhen Hepalink Pharmaceutical to fund immunotherapy for treatment of cancer in China

Shenzhen Hepalink Pharmaceutical Co

22/03/2016 13:30

March 22 (Reuters) - Quest Pharmatech Inc  QPT.V : 
    * Says subsidiary, Oncoquest Inc. has signed an agreement 
with Shenzhen Hepalink Pharmaceutical Co., Ltd 
    * Oncoquest will license Greater China rights to 
immunotherapy technologies and provide 1 million usd for 46% of 
shares of oncovent 
    * Agreement results in creation of a new company in china 
called Oncovent Co., Ltd valued at U.S. $9.26 million 
    * Hepalink will contribute 5 million USD for 54% of shares 
of Oncovent 
    * As part of agreement, Oncoquest will transfer  portion of 
shares in Oncovent to co such that co will own 11% of shares of 
Oncovent 
 
Source text for Eikon:  ID:nPnbqgYkMa  
Further company coverage:  QPT.V  
 
 (Bengaluru Newsroom: +1 646 223 8780)